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Abstract Background Several measures for calculating
adherence to one medication from dispensing data records
have been proposed, but the nomenclature is inconsistent
and computations vary. The same measures, like the
medication possession ratio (MPR), have been used for
multiple medication regimens, and have tended to over- or
under-estimate adherence rates. Objective To demonstrate
the impact of varying elements in MPR to a single medi-
cation regimen; to define standards for the estimation of
adherence to polypharmacy; to propose a new method for
calculating adherence to polypharmacy; to face validate it.
Setting Face validity of the proposed method. Method
Variations in the MPR formula were simulated. Standards
for the estimation of adherence to polypharmacy were
defined. A new method to calculate adherence to poly-
pharmacy was established. Its face validity with three
illustrative cases obtained from a pharmacy refill database
was assessed. Main outcome measure Adherence rate to
polypharmacy from refill data records. Results MPR to a
single medication is operationalized in the numerator and
denominator and is influenced by the parameters like
observation period, medication gaps, overlap. For poly-
pharmacy, an average MPR is commonly used, which is
not accounting for the specificity of multiple medications,
and hence overestimating adherence rate. We propose the
daily polypharmacy possession ratio (DPPR) as an index
of adherence to polypharmacy. It estimates the proportion
of time a patient had medication available for use by
considering the presence or absence of multiple medica-
tions on each day in the observation period. We calculated
possession rates from refill histories over 31 months
(January 1, 2011–July 31, 2013) for three illustrative
patients. The average MPR estimates were 80 % for a
patient with 6 medications/20 refill dates, 90 % for a
patient with 4 medications/11 refill dates, and 89 % for a
patient with 3 medications/17 refill dates. The corre-
sponding DPPRs were 75, 88 and 99 %, indicating over-
estimations by 5 and 2 %, and underestimation by 10 %,
respectively. Conclusion The DPPR accounts for the
specificity of polypharmacy including number of medica-
tions, medication switching, duplication, overlapping.
Research is needed to further confirm the validity of this
new index.
Keywords Adherence  Compliance  Daily
polypharmacy possession ratio  Medication
possession ratio  Pharmacy claims  Polypharmacy 
Refill data
Impact of findings on practice
• The Daily Patient Possession Ratio (DPPR) offers cli-
nicians and researchers a method for estimating
adherence to polypharmacy regimens.
• When calculating adherence to polypharmacy, the DPPR
avoids the overestimation inherent to using single-med-
ication records.
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Introduction
Because a patient’s medication-taking behaviour is a pre-
requisite for evaluating the effectiveness of medications [1]
accurate and consistent measurement of adherence is critical.
The advance of computerized pharmacy records in developed
countries that use medical informatics in their health system
enables the assessment of adherence to an index medication
based on refill patterns [2]. Several measures for calculating
adherence rate from secondary database have been proposed,
such as: medication possession ratio (MPR) and related mea-
sures of availability; discontinuation/continuation; switching;
medication gaps; refill compliance, and retentiveness/turbu-
lence [3]. All have in common that they measure the timeliness
of prescription or refills, not actual drug-taking, and use the
medication exposure time to estimate adherence. Conse-
quently, the measures quantify the patient’s possession of
medication and, thus, calculate the highest possible level of
medication consumption over a particular time frame.
Although there is no gold standard, MPR is the most commonly
used measure. It is calculated by dividing the days’ supply of a
medication dispensed by the number of days in the time
interval of interest. Another often used measure is the propor-
tion of days covered (PDC), which represents the proportion of
days a patient has a medication available in a given period of
time and uses indices truncated at 1.0 [4]. These measures are
widely used because dispensing databases contain the neces-
sary elements for calculation: (a) the quantity dispensed, which
usually is the package size or a multiple of it dispensed at one
time; or alternately for dispensing from bulk stock the number
of medications supplied at one time; (b) the prescribed daily
dosage, or the amount of medication to be consumed per day,
which is calculated as (pills per dose) 9 (dose per day); and
(c) the number of days’ supply, that is, the quantity dispensed
divided by the prescribed daily dosage.
Being derived from longitudinal dispensing databases, the
MPR and PDC can quantify long-term adherence and asso-
ciated outcomes. However, five definitions influence the cal-
culation of these measures and explain the variations in results
often seen. First, the observation period, i.e., the length of the
time over which adherence is assessed, may start and end at a
specific fill and refill date; on arbitrary start/stop dates that are
set as the index or inventory date and are independent from
fills and refills; or a combination of a fixed and an arbitrary
date. Second, an initial/terminal gap between dates of first/last
fill and arbitrary start/end dates may be present and can be
quantified as a proportion of time without supply. Third, an
interim gap may exist between refills when prior supply is
depleted before refill supply is available. Fourth, the number of
days’ supply dispensed at any fill/refill event may vary and
requires adjustments in the calculations. Alternately, and fifth,
overlap may occur as refill precedes depletion of the quantity
from a prior dispensing, and leads to stock piling of
accumulated supply. These five sources of bias may lead to an
under- or over-estimation of adherence to a single-medication.
The effects of these five sources of bias are likely to be
amplified when adherence to a polypharmacy regimen is
estimated using methods for single-medication adherence
such as the MPR or, as commonly done, averaging the MPR of
each medication in the polypharmacy regimen. Polyphar-
macy is common due to comorbidities [5], an aging popula-
tion [6], clinical practice relying on multi-drug combinations
[7], or evidence-based guidelines recommending synergistic
drug combinations [8]. Polypharmacy is different from regi-
men complexity, which refers to the number of daily doses for
a medication, the presence of non-oral routes of administra-
tion, and the need for specific dosing instructions [9]. Because
polypharmacy is known to be associated with medication non-
adherence [10] because of the greater number of medications
that can be missed on a daily basis, the assessment of adher-
ence to the entire polypharmacy regimen is essential. Further,
because irregular and inconsistent intake of one or more drugs
in a polypharmacy regimen is common and may impact on
clinical outcomes, assessment of adherence to polypharmacy
is clinically relevant. The few studies that have attempted to
calculate adherence to several concurrent medications have
averaged the indices obtained for each of the single-medica-
tions [11–15]. This method has been shown to overestimate
[16] but may also underestimate adherence to polypharmacy
regimens.
Aim and objectives
In the absence of an integrated method for assessing adherence
to polypharmacy regimens and the estimation errors likely
from averaging methods, our aim was to develop a new
method for quantifying adherence to polypharmacy regimens.
Five objectives applied: (1) to document the estimation bias in
single-medication adherence as a function of the sources of
variation identified above; (2) to document the estimation bias
resulting from averaging single-medication methods to poly-
pharmacy regimens; (3) to specify the standards for calculat-
ing an integrated measure of polypharmacy adherence; (4) to
define the proposed method for calculating adherence to pol-
ypharmacy regimens; and (5) to establish initial face validity
of the method by applying to three illustrative cases obtained
from the dispensing records of a community pharmacy.
Methods
Estimation bias in single-medication adherence
We constructed a hypothetical refill scenario commonly
seen in reimbursement records for medicines for long-term
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conditions in order to illustrate the impact of variable
elements on the calculations of adherence to single-medi-
cation such as hypertension. We selected seven dispensa-
tions in analogy to Steiner et al. [14] and calculated several
indices. Two different observation periods of 250 days
each were used: (1) from the first fill to the last refill date;
and (2) over two arbitrary dates. Four calculations were
performed:
1. The proportion of supply between dispensations or
adherence in one refill interval (An/Bn), calculated as
the days’ supply obtained at the beginning of a specific
interval divided by the days elapsed before the
subsequent fill and expressed as a percentage.
2. The days without supply between dispensations or
gaps in one refill interval (Gn = Bn - An), calculated
as the days elapsed before the subsequent fill i.e., the
number of days between dispensations, minus the
days’ supply obtained at the beginning of the interval.
3. The proportion of time with adequate supply or





as the total days’ supply obtained over the observation
period and across all time intervals divided by the
number of days of the observation period and
expressed as a percentage.
4. The proportion of time without adequate supply or





as the total days of gaps (?) or surplus (-) divided by
the total days to next dispensation or to end of
observation period; that is, the cumulative sum of the
number of days between dispensations minus the total
days’ supply divided by the number of days in the
observation period.
Estimation bias in polypharmacy adherence calculated
with averaging methods
We again constructed a hypothetical scenario, this one
involving 3 medications with a combined 15 refills [17]
and an observation period beginning with the initial fill at
the start date and ending with the medication review.
Medication 1 came in a package size of 14 with seven
refills at days 1, 15, 29, 43, 57, 71, 101 and end date at
110 days. Medication 2 came in a package size of 30 with
four refills at days 1, 41, 61, 120 and end date at 120 days.
Medication 3 came in package size of 60 with four refills at
days 1, 31, 51, 101 and end date at 110 days.
Specification of standards
On the basis of the above bias estimation exercises, prior
review work, and literature evidence, calculation standards
were set to assure uniformity in calculations.
Development of method
A proposed method based on these standards was devel-
oped and evaluated for arithmetic accuracy.
Initial assessment of face validity
We applied the method to three illustrative cases varying in
the number of medications and refills obtained from the
dispensing data records of a community pharmacy in Basel,
Switzerland.
Results
Estimation bias in single-medication adherence
Figure 1 depicts the adherence calculations for a patient
with a chronic condition with a hypothetical refill scenario
of a medication to be taken once daily with 7 dispensations
in analogy to Steiner et al. [14]. Table 1 summarizes the
calculated adherence rates between each refill event and the
next.
Table 2 presents the days without supply between dis-
pensations (or gaps).
Table 3 summarizes the MPR results. The overall pos-
session rates are 108 %/84 % if calculations consider all
values without the last refill, and 93 %/87 % if single
values are capped at 1.0, underscoring that adherence is
underestimated with truncated values.
Table 4 presents the proportion of time without ade-
quate supply (or gaps) over all refill intervals. The pro-
portion of gaps is -0.08/0.04 if calculations consider all
values and 0.14/0.22 if negative values are set to zero, thus
masking the surplus (negative gaps’ value). If accumulated
oversupply is assumed to be used when the supply is
exhausted and carryover from one interval to the next is
allowed, the proportion of time without medication
declines from 35 to 25 days, which corresponds to an
overall 4 % improvement in supply.
Estimation bias in polypharmacy adherence calculated
with averaging methods
Figure 2 graphs the average MPR calculation with a
hypothetical scenario of 3 medications with a combined 15
refills. Note that the observation period begins with the first
refill at start date ‘‘day 1’’ and runs until the medication
review (an arbitrary date). The MPR for medication 1 is
(7 9 14)/110 = 89 %; for medication 2 it is (4 9 30)/
120 = 100 %; and for medication 3 it is (4 9 60)/
110 = 218 %. Hence the average MPR is
[(7 9 14) ? (4 9 30) ? (4 9 60)]/
194 Int J Clin Pharm (2014) 36:192–201
123
(110 ? 120 ? 110) = 135 %, denoting an overconsump-
tion of medication.
Specification of standards
The average MPR calculation does not control for the
influence of several medications having been prescribed,
across varying schedules, and the expectation that patients
adhere to all medications regardless of regimen. Further,
patients rarely refill a medication on exactly the day fol-
lowing the last day of use of the previous dispensing. In
addition, because of different package sizes, patients may
have refills due on different dates. As a consequence, they
adapt their refill obligation to daily duties and schedules
and may refill a prescription earlier (overlap of two dis-
pensations, surplus) or later (gap without supply between
two dispensations). Thus, apparently excessive or insuffi-
cient refill patterns may be misinterpreted as oversupply or
lack of medication, when they may represent daily life
days‘ supply

































Fig. 1 Scenario of adherence to a single-
medication, starting at the first fill (dark,
bold line) or an arbitrary date (grey, dotted
lines) over an observation period of
250 days (arbitrary end date). RnX = refill
number and quantity dispensed;
An = number of days’ supply;
Bn = interval between dispensations; gaps
indicate number of days with no medication.
Note the arrows from R2 to R3 indicate
carryover of excess medication from one
interval to the next interval
Table 1 Estimates of single-medication adherence between each refill event and the next, for each observation period (starting at a refill date or
an arbitrary date)
Refill event R1 R2 R3 R4 R5 R6























R(number) refers to interval starting at a given refill event and ending at the next refill event; e.g., R1 is refill event 1 and the interval ends with
R2
Table 2 Days without supply between dispensations (or gaps), for each observation period (starting at a refill date or an arbitrary date)
Refill event R1 R2 R3 R4 R5 R6



































A positive value indicates a lack of supply, a negative value indicates a surplus of supply
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conditions such as foresight before holidays or using up all
medication before the next refill.
We propose new definitions of the parameters needed to
calculate medication possession rates with refill data
(Table 5). In the numerator, extra doses beyond the end of
the observation period should be excluded (no oversupply);
therapeutic switching and therapeutic duplication should be
considered as one medication (no duplication), and changes
in dosage should be recognised and accounted for. In the
denominator, the observation period should start at the first
dispensation date, end either at the last refill date or at the
medication review date, and cover at least two refills (no
gaps). Finally, the carryover of excess medication from one
interval to the next interval should be allowed, yet without
retroactive compensation.
Table 3 Medication possession ratio (MPR) calculated over all refill intervalls, with or without the last refill, and with single values capped at
1.0, for each observation period (starting at a refill date or an arbitrary date)
Specifications With last refill Without last refill With single values capped at 1.0




(0.86 ? 1 ? 0.70 ? 1 ? 1 ? 1)/6
(93 %)




(0.67 ? 1 ? 0.70 ? 1 ? 1)/5
(87 %)
Table 4 Proportion of time without adequate supply (or gaps) over
all refill intervals, with all values or negative values set at zero (no
surplus), for each observation period (starting at a refill date or an
arbitrary date)




(10 - 10 ? 25 -
20 - 5 - 20)/250
(-0.08)





(30 - 10 ? 25 -
20 - 15)/250
(0.04)
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average MPR
= 135%
Fig. 2 Scenario of adherence to a combined drug regimen for a
patient (with a chronic condition) with a medication to be taken once
daily in analogy to [17]. The refills of 3 medications are depicted with
15 dispensations over an observation period defined between the first
fill (R1 at day 1, start date) and a medication review (arbitrary end
date). R refill number; box with number quantity dispensed
Table 5 New definitions proposed of the parameters required to
calculate possession rates with refill data
New definitions of the parameters Pros




End the observation period at the last refill
date or at the medication review date
No artificial terminal
gaps
Exclude any extra doses of the last




Allow the carryover of excess medication




Exclude patients with two refills or less No artificial gaps
Consider therapeutic switchinga as one
medication and not as a duplication
No artificial
duplication
Consider switching from two medications to
one combination pill as therapeutic
switching, with the first refill in time
determining the index medication
substituted by the combination pill
No artificial
duplication




Consider therapeutic duplicationb as one
medication, with the index medication being
the one with the first refill in time
No artificial
duplication




a Medication switch occurs when a subject initially fills a prescription
for one product, then at a later point fills a prescription for a different
product in the same therapeutic class and never refills the first product
within the observation period
b Therapeutic duplication is defined as multiple medication use
within the same therapeutic class, and can result from therapeutic
augmentation; prescription error must be excluded
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New method for calculating adherence
to polypharmacy
With these definitions, we posit that the numerator cannot
merely be the sum of the days’ supply, that each day should
be assessed independently, and that the proportion of daily
medications on-hand be calculated. We propose as new
index the daily polypharmacy possession ratio (DPPR).
The method is as follows: Look at each day in the obser-
vation period separately, and determine how many medi-
cations are available, set a score between 0 (no medication
available) and 1 (all medications available) weighted by the
number of medications to be taken each day, resulting in
daily scores indicating the proportion of medications
available for each day. Sum the scores and divide by the
number of days in the observation period to obtain the
proportion of all medications available for daily use.
Figure 3 shows the calculation of the DPPR for 3
medications to be taken once daily with 15 dispensations
over the same observation period as used in Fig. 2. Each
daily score can take a value of 1 (all medications avail-
able), 2/3 (two medications available), 1/3 (one medication
available) or 0 (no medication available). The sum of the
daily scores (10 9 1/1) ? (20 9 3/3) ? (10 9 2/
3) ? (54 9 3/3) ? (6 9 2/3) ? (10 9 1/3) ? (9 9 2/
3) ? (1 9 3/3) is 104.9. Next 104.9/120 = 87.5 % yields
the DPPR and represents the weighted percentage of
medications available. The accumulated surplus of daily
doses is 80 (medication 1). The accumulated number of
days with at least one missing dose is 16 for medication 1
(4.7 %) ? 30 for medication 2 (8.8 %) = 46 (13.5 %).
The DPPR requires a ‘‘supply diary’’ for each patient-
day. Because overuse or excess prescription of medications
cannot be detected with the DPPR, the surplus of daily
doses and the total number of missed doses (gaps) during
the observation period should be evaluated to complete the
description of the observed population.
Initial assessment of face validity
Three patients with polypharmacy using a single commu-
nity pharmacy in Basel (Switzerland) were selected by the
pharmacist who subjectively and clinically identified an
adherer, an underadherer and an overadherer. The medi-
cation histories between January 1, 2011 and July 31, 2013
were retrieved from the pharmacy database. They include 1
male (M1) and 2 female (F1, F2) patients; aged 72, 78 and
74 years; with 4, 3 and 6 medications daily; and 11, 17, and
20 refill dates over the observation period of 31 months,
respectively (Box 1).
The results are presented in Box 1. The MPRs were
calculated with the average MPR method and yielded 90 %
for patient M1, 89 % for patient F1, and 80 % for patient
F2. With the DPPR method and the standards defined
above, the DDPR rates were 88, 99 and 75 %, respectively.
The mean numbers of days without supply (gaps) were
-10, -1 and -24 %, respectively.
Discussion
The two methods most often used to measure medication
adherence from dispensing data records are the MPR and
the PDC. However, because of lack of standards and def-
initions necessary for the parameters used in calculation,
the methods described in studies vary widely. As an
example, Hess et al. [18] calculated adherence rates rang-
ing from 63.5 to 104.8 % when applying 11 different cal-
culation methods to the same set of pharmacy data. As a
consequence, comparing results between studies is often
difficult if not impossible. Further, many assumptions are
made when adherence rates (i.e., medication consumption)
are calculated from secondary databases; e.g., that a person
has the medication available on the day of the prescription;
that patients consume the medication as prescribed; that
patients start taking the medication on the day of dispen-
sation until the supply is exhausted; that medication con-
sumption is consistent throughout the observation period;
or that all extra doses accumulated during the observation































Fig. 3 Calculation of daily polypharmacy possession rate DPPR for 3
medications to be taken once daily, with 15 dispensations over an
observation period defined between the first fill (R1 at day 1, start
date) and a medication review (end date), same as in Fig. 2. Daily
possession is depicted as follow: all medications available (score of 1,
black bar), two medications available (score of 2/3, dark grey bar),
one medication available (score of 1/3, light grey bar). The arrow
indicates carryover of excess medication from one interval to the next
interval
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Patient F1 No days in the interval Quantity dispensed at the refill date of the medication (prescribed daily dosage)






18.01.11 100* 98 –
18.03.11 59 100* 98 100
14.05.11 57 100 0 0*
27.06.11 44 100 98 100
12.08.11 46 100 0 0
01.10.11 50 100 98 100
21.11.11 51 100* 0 0*
23.01.12 63 100 98 100
01.03.12 38 100 0 0
16.04.12 46 100 98 100
19.06.12 64 100 0 0
02.08.12 44 200* 98 100*
20.11.12 110 100 98 100
31.12.12 41 100 0 0
19.02.13 50 100 98 100
08.04.13 48 100 0 0
25.05.13 47 100 98 100
16.07.13 52 200 0 100
31.07.13 15
Box 1 Medication histories of three illustrative patients (M1, F1, and F2) between the start date (January 1, 2011) and an arbitrary review date
(July 31, 2013), with indication of the prescribed daily dosage (e.g., 1–0–0 stands for one tablet every morning), number of days in the single
intervals and in the observation period (total); quantity dispensed at the refill date and total of days’ supply (calculated as quantity dispensed
divided by the prescribed daily dosage), and total number of days without supply (gaps). Asterisks (*) indicate insufficient supply for the next
interval
Patient M1 No days in the interval Quantity dispensed at the refill date of the medication (prescribed daily dosage)






Salmeterol 25 lg ? fluticason 250 lg
(1–0–0)
11.01.11 100 – 90 60*
05.04.11 84 100* – 196 60*
11.10.11 189 100 100 98 60*
12.01.12 93 100 100 98 60
07.03.12 55 100 100 98 60*
27.06.12 112 0* 0* 0 60
08.08.12 42 100* 100* 98* 120
07.12.12 121 100 100 98 60*
27.02.13 82 100 100 98 60
23.04.13 55 0 0 0 60
14.06.13 52 100 100 98 120
31.07.13 47
Total 932 900 700 972 780
Total gaps -96 -23 -18 -238
Calculation: ‘‘average MPR’’ = [(900 ? 700 ? 972 ? 780)/4]/932 = 90 %
DPPR = [(60 9 3/3 ? 24 9 2/3) ? (60 9 3/3 ? 56 9 2/3 ? 73 9 1/3) ? (60 9 4/4 ? 33 9 3/4) ? 55 9 4/4 ? (65 9 4/4 ? 47 9 3/
4) ? (40 9 4/4 ? 2 9 2/4) ? (100 9 4/4 ? 3 9 2/4 ? 18 9 1/4) ? (77 9 4/4 ? 5 9 3/4) ? 55 9 4/4 ? 52 9 4/4 ? 47 9 4/4]/
932 = 88 %
Gaps: mean -10 %
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not obtained on time or before the next refill [19]. This
might explain why some studies specify corrections for
values, often without a clear rationale, like setting negative
values to zero [17] or multiplying duration of drug use by
factor 1.1 to control for irregular use and early drug dis-
pensation [20].
continued
Patient F1 No days in the interval Quantity dispensed at the refill date of the medication (prescribed daily dosage)






Total 925 1,000 980 1,000
Total gaps -22 0 -13
Calculation: ‘‘average MPR’’ = [(500 ? 980 ? 1,000)/3]/925 = 89 %
DPPR = [(50 9 2/2 ? 9 9 1/2) ? (50 9 3/3 ? 7 9 2/3) ? (43 9 3/3 ? 1 9 2/3) ? 46 9 3/3 ? 50 9 3/3 ? 51 9 3/3 ? (53 9 3/
3 ? 6 9 2/3 ? 4 9 1/3) ? 38 9 3/3 ? 46 9 3/3 ? 64 9 3/3 ? 44 9 3/3 ? (108 9 3/3 ? 2 9 1/3) ? 41 9 3/3 ? 50 9 3/3 ? 48 9 3/
3 ? 47 9 3/3 ? 52 9 3/3 ? 15 9 3/3]/925 = 99 %
Gaps: mean -1 %
Patient
F2
No days in the
interval





















04.01.11 120 98 – – – –
10.02.11 37 120 196 – 98 100 240
03.05.11 82 0* 0 28* 0* 0 0*
21.06.11 49 120 0 0* 98 0 120
04.08.11 44 240 0 98 0* 0* 0*
18.10.11 75 0 0* 0 196 0* 0*
08.11.11 21 0 98 0* 0 0* 0*
03.12.11 25 0* 0 0* 0 100 120
03.01.12 31 120* 0* 98 0 0 0*
15.03.12 72 120 98 0* 98 0 0*
14.05.12 60 120 0 0* 0 0 0*
04.06.12 21 0 0* 98 0 0* 0*
25.06.12 21 0* 98 0 98 0* 0*
25.08.12 61 120 98 98 0 100 0*
20.10.12 56 240 0* 98 98 0 240
25.01.13 97 120 98 0 0* 0 0*
25.02.13 31 0 0 0* 0* 0* 120
05.04.13 39 120 98 98 0* 0* 0*
13.05.13 38 0* 0 0* 0* 100 0*
13.07.13 61 0* 98 98 98 0 120
31.07.13 18
Total 939 780 980 714 784 800 480
Total
gaps
-159 -66 -186 -204 -223 -497
Calculation: ‘‘average MPR’’ = [(780 ? 980 ? 714 ? 784 ? 800 ? 480)/6]/939 = 80 %
DPPR = [37 9 2/2 ? 82 9 5/5 ? (1 9 6/6 ? 15 9 5/6 ? 12 9 4/6 ? 10 9 3/6 ? 11 9 2/6) ? 44 9 5/6 ? (16 9 6/6 ? 9 9 5/
6 ? 29 9 4/6 ? 21 9 3/6) ? (7 9 4/6 ? 14 9 3/6) ? (2 9 4/6 ? 23 9 3/6) ? (15 9 5/6 ? 16 9 4/6) ? (29 9 6/6 ? 13 9 5/
6 ? 18 9 4/6 ? 12 9 3/6) ? (26 9 5/6 ? 34 9 4/6) ? 21 9 4/6 ? (16 9 5/6 ? 1 9 4/6 ? 4 9 3/6) ? (18 9 4/6 ? 43 9 3/6) ? 56 9 5/
6 ? (79 9 6/6 ? 18 9 5/6) ? (23 9 6/6 ? 2 9 5/6 ? 6 9 4/6) ? (16 9 5/6 ? 12 9 4/6 ? 11 9 3/6 ? (13 9 4/6 ? 25 9 3/
6) ? (39 9 4/6 ? 21 9 3/6 ? 1 9 2/6) ? 18 9 5/6)]/939 = 75 %
Gaps: mean -24 %
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To enable a more uniform presentation of data and thus
improve the consistency and quality of adherence analyses,
international experts developed a checklist of key issues on
how to perform retrospective analyses of refill medication
databases [21]. Unfortunately, the proposed measurements
of adherence lack key details and procedures, such as rules
to avoid double-counting covered days or handling over-
supply. It is evident that accurate calculation of adherence
rates from refill data requires standard definitions of the
considered time frame, the numerator and denominator,
and the management of missing values and/or time periods.
A more subtle calculation has been advocated [16] to allow
for the comparison of results across studies and the trans-
lation to real world practice. With the advance of com-
puterized pharmacy records, some researchers developed
computational frameworks to detect such events as medi-
cation lapses in refill databases [22]. However, these
technical developments are only useful for individual
patient information and need further evaluation.
The influence of variable terms on the assessment of
adherence to single drug is amplified with multiple drug
assessment, especially when the method used is indifferent
to the specific settings. A study comparing different cal-
culation methods showed that the use of MPR for more
than one medication overestimates adherence, predomi-
nantly due to the presence of duplication [4]. Since the
‘‘average MPR’’ does not account for the number of
medications, the frequency of medication switching, the
duplication, the overlapping, or the unexpected and same-
day refills, it can hardly reflect the actual adherence that it
was intended to measure. Thus, MPR methods are inade-
quate for quantifying adherence to polypharmacy
regimens.
In this article, we defined new standards for the calcu-
lation of possession rates with refill data and proposed a
new index, the DPPR. This index considers the presence or
absence of multiple medications on each day in the
observation period. It quantifies polypharmacy adherence
as the percentage of medications daily available. This
approach accounts for the specificity of polypharmacy such
as the number of medications and frequency of medication
switching. It also eliminates duplication and overlapping,
the parameters responsible for the general overestimation
of adherence. With the three illustrative cases we selected
in a community pharmacy over 31 months, we piloted the
new method and demonstrated its face validity in daily
practice. As predicted, the DPPR values were lower than
the average MPR estimates. Thus, we posit that the DPPR
is closer to the actual adherence rate than other
calculations.
Our approach has several strengths. First, we propose a
standardization of the parameters used for calculation.
Second, we propose a method that is insensitive to
oversupply and duplication, the two parameters in mathe-
matical calculations that lead to overestimation of adher-
ence rates. Third, the DPPR represents a continuous index
of adherence across all subjects rather than a threshold-
based index, separating adherent from non-adherent sub-
jects. Moreover, the conversion from continuous data into
categorical data as well as the use of cut-points is only
recommended when the clinical validity of the specified
level of adherence has been demonstrated [21]. To our
knowledge, this exists only for oral contraceptives and HIV
drugs [23].
Our new index also has limits. First, the DPPR cannot
detect oversupply. Thus, we propose to indicate addition-
ally the evaluation of the accumulated surplus (oversupply)
and the accumulated days with at least one missing medi-
cation (gaps). Second, the DPPR requires a ‘‘supply diary’’
for each patient-day. This may be difficult to generate by
computer, mainly because dispensing and recording ser-
vices may differ across countries. For example, European
pharmacies dispense manufactured packagings of varying
sizes while US pharmacies have access to bulks and dis-
pense the exact number of units prescribed. The maximum
quantity of dispensed drugs is usually 90 days in the
Netherlands, with a maximum of 15 days for the first dis-
pensing, while no such restriction exists in Switzerland or
Germany, where the first dispensed package can be 100
tablets in size. Finally, calculation with variable dosage
schedule (e.g., ‘‘take 1 or 2 pills…’’) or ‘‘as needed’’ as part
of the instructions is not possible and these medications are
to be disregarded from the evaluation.
Conclusion
Estimates of adherence to single-medications obtained
from MPR-based methods may vary because of differences
in calculation methods. This problem is amplified by
multiple factors outlined in this article. Because adherence
to multiple medications has been assessed with methods
developed for single-medication use, results have so far
proved divergent. We propose new definitions to stan-
dardize the parameters needed to calculate possession rates
with secondary databases. We further propose a new
method to calculate possession rate with multiple medi-
cations that accounts for the specificity of polypharmacy.
Studies are needed to validate the new index DPPR, pref-
erably with a national database. Subsequently, defining of a
formula and programming of codes for computer-generat-
ing the DPPR from dispensing data records should be
considered.
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